{"product_id":"understanding-thyroid-cancer-diagnosis-in-the-era-of-precision-imaging-a-patients-guide","title":"Understanding Thyroid Cancer Diagnosis in the Era of Precision Imaging: A Patient's Guide","description":"\u003cp\u003eThyroid cancer affects 1.3% of the population, and its incidence has been rising by roughly 2% per year over the past decade. While most common types of thyroid cancer carry an excellent prognosis—with a 98% five-year survival rate—some aggressive subtypes remain deadly, and death rates have been slowly climbing by about 0.7% per year. This review from researchers at City of Hope National Medical Center examines how modern imaging technologies, including ultrasound, SPECT, CT, PET\/CT, MRI, and the newer PET\/MRI, are transforming the way thyroid cancer is detected, diagnosed, and managed. The authors also highlight emerging genetic testing and \"theranostic\" approaches that combine diagnosis and treatment, ushering in a new era of precision medicine for thyroid cancer patients.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Thyroid Cancer Diagnosis in the Era of Precision Imaging: A Patient's Guide\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#epidemiology\"\u003eEpidemiology: How Common Is Thyroid Cancer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#subtypes\"\u003eThyroid Cancer Subtypes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#genetics\"\u003eGenetics and Risk Factors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ultrasound\"\u003eUltrasound: The First Line of Defense\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#spect\"\u003eSPECT Scans: Tracking Iodine in the Body\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ct\"\u003eCT Scans: Finding Incidental Nodules\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#petct\"\u003ePET\/CT Scans: Detecting Aggressive Tumors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mri\"\u003eMRI: Detailed Soft Tissue Imaging\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#petmri\"\u003ePET\/MRI: Combining Two Powerful Technologies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#theranostics\"\u003eTheranostics: Combining Diagnosis and Treatment\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eClinical Implications for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Review\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eAbout 1.3% of people develop thyroid cancer, with a 98% five-year survival, but anaplastic thyroid cancer carries a median survival of 3–7 months.\u003c\/li\u003e\n\u003cli\u003eIncidental thyroid nodules appear on up to 65% of chest CT scans; about 5% are malignant, so suspicious ones need ultrasound follow-up.\u003c\/li\u003e\n\u003cli\u003eTI-RADS scoring helps decide which nodules need biopsy: TR5 lesions 1 cm or larger generally warrant fine needle aspiration.\u003c\/li\u003e\n\u003cli\u003eFDG PET\/CT is preferred for aggressive, de-differentiated thyroid cancers that are invisible on iodine scans, though infection and inflammation can cause false positives.\u003c\/li\u003e\n\u003cli\u003eTheranostics, like radioactive iodine, combines imaging and therapy in one agent, enabling diagnosis and treatment of differentiated thyroid cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer is the most common endocrine (hormone-gland) cancer and the 12th most common cancer among all cancer types. The past decade has brought a major shift in how this disease is detected. Doctors now find thyroid cancers not only when a patient feels a lump in the neck or during a routine physical exam, but increasingly as an \"incidental\" finding—a suspicious nodule discovered on a CT scan of the chest, a carotid ultrasound, or a PET scan that was originally ordered for an unrelated health problem.\u003c\/p\u003e\n\n\u003cp\u003eOnce a suspicious nodule is found, patients typically undergo a diagnostic work-up that includes laboratory blood tests, additional imaging, and often a biopsy (tissue sampling). Accurate diagnosis is essential for clinical staging and designing the best treatment plan for each patient.\u003c\/p\u003e\n\n\u003cp\u003eThis review article, published in the \u003cem\u003eJournal of Thoracic Disease\u003c\/em\u003e, was written by a team of radiologists, surgeons, and imaging specialists. Their goal was to explain the utility of various imaging modalities in thyroid cancer diagnosis and management, and to highlight emerging diagnostic techniques that improve diagnostic specificity and accuracy. The ultimate aim is to pave the way for precision medicine—care that is tailored to each individual patient's tumor characteristics.\u003c\/p\u003e\n\n\u003ch2 id=\"epidemiology\"\u003eEpidemiology: How Common Is Thyroid Cancer?\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer affects \u003cstrong\u003e1.3% of the population\u003c\/strong\u003e, and the numbers are growing. The incidence of thyroid cancer is \u003cstrong\u003ealmost double\u003c\/strong\u003e what it was in the year 2000, now accounting for \u003cstrong\u003e2.1% of all cancer diagnoses\u003c\/strong\u003e worldwide. Over the last decade, the rate of new cases has increased by approximately \u003cstrong\u003e2% per year\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe median 5-year survival rate for thyroid cancer was \u003cstrong\u003e98%\u003c\/strong\u003e between 2009 and 2015. However, this encouraging statistic masks a troubling trend: there has been a slow but steady increase in the rate of deaths associated with thyroid cancer—approximately \u003cstrong\u003e0.7% per year\u003c\/strong\u003e over the last decade.\u003c\/p\u003e\n\n\u003cp\u003eCertain groups face different risks and outcomes. Between 1974 and 2013, the mean age of thyroid cancer diagnosis was \u003cstrong\u003e48 years old (with a standard deviation of 16 years)\u003c\/strong\u003e. Women are more commonly affected than men, accounting for \u003cstrong\u003e75% of all diagnoses\u003c\/strong\u003e. The geriatric (elderly) population has an increased incidence of thyroid cancer and also tends to have a worse prognosis, in part because they experience increased treatment-related complications and mortality.\u003c\/p\u003e\n\n\u003cp\u003eOne of the challenges doctors face is the high recurrence rate. Thyroid cancer comes back in approximately \u003cstrong\u003e20% of patients\u003c\/strong\u003e. The ability to distinguish between a true recurrence and treatment-related tissue changes is critical to improving survival. This is exactly where precision imaging plays a vital role.\u003c\/p\u003e\n\n\u003ch2 id=\"subtypes\"\u003eThyroid Cancer Subtypes\u003c\/h2\u003e\n\n\u003cp\u003eThere are four major subtypes of thyroid cancer:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePapillary thyroid cancer (PTC)\u003c\/strong\u003e — the most common, accounting for about 85% of all thyroid cancers\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eFollicular thyroid cancer (FTC)\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnaplastic thyroid cancer (ATC)\u003c\/strong\u003e — rare but extremely aggressive\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eMedullary thyroid cancer (MTC)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLess common subtypes include \u003cstrong\u003eHurthle cell carcinoma (HTC)\u003c\/strong\u003e and \u003cstrong\u003epoorly differentiated thyroid cancer (PDTC)\u003c\/strong\u003e. PTC, FTC, and HTC are known as \"well-differentiated\" subtypes, and together they account for approximately \u003cstrong\u003e95% of all thyroid cancers\u003c\/strong\u003e. These subtypes generally have a much better prognosis than PDTC and ATC.\u003c\/p\u003e\n\n\u003cp\u003eThe differences between subtypes matter enormously for patient outcomes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnaplastic thyroid cancer (ATC)\u003c\/strong\u003e accounts for less than 1% of all thyroid cancers, but its median survival is only \u003cstrong\u003ethree to seven months\u003c\/strong\u003e, and the 1-year survival rate is just \u003cstrong\u003e10–20%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePapillary thyroid cancer\u003c\/strong\u003e most commonly spreads through lymph nodes (nodal metastasis). Prior radiation exposure is the most common risk factor, especially for PTC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFollicular thyroid cancer\u003c\/strong\u003e is more likely to spread through the bloodstream (hematogenous spread), typically to the lungs and bones.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePoorly differentiated thyroid cancer\u003c\/strong\u003e is locally aggressive, invading adjacent structures such as the trachea (windpipe) and blood vessels, and can also spread through the bloodstream.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedullary thyroid cancer\u003c\/strong\u003e develops from the parafollicular neuroendocrine cells in the thyroid and often metastasizes to the cervical (neck) lymph nodes.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eUnderstanding how each subtype behaves locally and how it tends to spread is integral to planning diagnostic work-ups and treatment strategies. For instance, the review presents the case of an 82-year-old female diagnosed with metastatic medullary and classical papillary thyroid carcinoma, whose ultrasound showed microcalcifications—tiny calcium deposits that are a warning sign of malignancy.\u003c\/p\u003e\n\n\u003ch2 id=\"genetics\"\u003eGenetics and Risk Factors\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer is driven by specific genetic mutations, and identifying these mutations has become essential in the era of precision medicine. The most common mutations are found in the \u003cstrong\u003eBRAF\u003c\/strong\u003e and \u003cstrong\u003eRET\u003c\/strong\u003e genes, as well as in \u003cstrong\u003ePAX8\/PPARγ\u003c\/strong\u003e gene rearrangements. These mutations alter two critical cellular signaling pathways: the \u003cstrong\u003eMAPK\u003c\/strong\u003e pathway and the \u003cstrong\u003ePI3K-AKT\u003c\/strong\u003e pathway.\u003c\/p\u003e\n\n\u003cp\u003eHere is what the research shows about how these mutations map to specific thyroid cancer subtypes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA mutation in the \u003cstrong\u003eBRAF\u003c\/strong\u003e gene occurs in \u003cstrong\u003e40–45% of de novo papillary thyroid cancers\u003c\/strong\u003e (cancers that arise without prior radiation exposure).\u003c\/li\u003e\n  \u003cli\u003ePatients with prior radiation exposure most commonly have \u003cstrong\u003eRET\u003c\/strong\u003e mutations.\u003c\/li\u003e\n  \u003cli\u003eThe most common mutation in \u003cstrong\u003efollicular thyroid cancer (40–50%)\u003c\/strong\u003e and \u003cstrong\u003epoorly differentiated thyroid cancer (20–40%)\u003c\/strong\u003e is in the \u003cstrong\u003eRAS\u003c\/strong\u003e gene.\u003c\/li\u003e\n  \u003cli\u003eA mutation in the \u003cstrong\u003eTP53\u003c\/strong\u003e gene occurs in \u003cstrong\u003e50–80% of anaplastic thyroid cancers\u003c\/strong\u003e and is generally not seen in well-differentiated carcinomas like PTC and FTC.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMedullary thyroid cancer\u003c\/strong\u003e is unique: the \u003cstrong\u003eRAS\u003c\/strong\u003e mutation is present in \u003cstrong\u003emore than 95% of familial (inherited) forms\u003c\/strong\u003e, but only in about \u003cstrong\u003e25% of sporadic (non-inherited) forms\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eGenetic testing is increasingly part of routine care at academic institutions. \u003cstrong\u003eThyroSeqv2™\u003c\/strong\u003e is a next-generation sequencing (NGS) panel that is being used to diagnose thyroid neoplasms that were previously classified as \"indeterminate cytology\" (meaning the biopsy results were not clearly benign or malignant). The review also cites important research in this area:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eChudova et al.\u003c\/strong\u003e used algorithms to differentiate between benign and malignant tumors using gene expression profiles.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWylie et al.\u003c\/strong\u003e utilized miRNA gene expression profiles and somatic gene alterations to develop molecular classifications of thyroid cancer.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSanler et al.\u003c\/strong\u003e analyzed the connection between germline mutations (inherited changes) in DNA repair genes and the risk of developing thyroid cancer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAs precision medicine grows, diagnostic and treatment strategies built around genetic mutations will likely become standard practice in both academic and community settings.\u003c\/p\u003e\n\n\u003ch2 id=\"ultrasound\"\u003eUltrasound: The First Line of Defense\u003c\/h2\u003e\n\n\u003cp\u003eUltrasound is the initial imaging modality of choice to evaluate thyroid nodules and to distinguish benign (non-cancerous) from neoplastic (cancerous) nodules. It is cost-effective, readily available, and does not expose patients to ionizing radiation.\u003c\/p\u003e\n\n\u003cp\u003eThyroid nodules with suspicious features are often biopsied using \u003cstrong\u003eultrasound-guided fine needle aspiration (FNA)\u003c\/strong\u003e. Ultrasound is not only useful for detecting the primary tumor; it also evaluates the lymph nodes in the neck (locoregional lymph nodes) for signs of metastasis. Surgeons frequently use ultrasound guidance during operative planning to ensure that all suspicious nodules and lymph nodes are removed.\u003c\/p\u003e\n\n\u003cp\u003eOn diagnostic ultrasound, thyroid nodules are characterized based on several key features:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSize\u003c\/li\u003e\n  \u003cli\u003eMargins (the border between the nodule and normal tissue)\u003c\/li\u003e\n  \u003cli\u003eEccentric location of the solid portion\u003c\/li\u003e\n  \u003cli\u003eHypoechogenicity (the nodule appears darker than surrounding thyroid tissue)\u003c\/li\u003e\n  \u003cli\u003eMicrocalcification (tiny calcium deposits)\u003c\/li\u003e\n  \u003cli\u003eIrregular shape\u003c\/li\u003e\n  \u003cli\u003eWhether the tumor is \"taller than it is wide\" (a shape that suggests malignancy)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese features help doctors distinguish benign from malignant nodules. For example, \u003cstrong\u003eirregular margins and microcalcifications are associated with malignant nodules\u003c\/strong\u003e, while small subcentimeter (less than 1 cm) spongiform avascular nodules are considered benign. The review illustrates this with the case of a 60-year-old female whose ultrasound revealed multiple micropapillary carcinomas with microcalcification and increased vascularity.\u003c\/p\u003e\n\n\u003ch3\u003eThe Bethesda System for Reporting Thyroid Cytopathology\u003c\/h3\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eBethesda System (BSRTC)\u003c\/strong\u003e is a diagnostic classification system based on FNA cytology (the microscopic examination of cells obtained from a biopsy). It has six diagnostic categories:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eNon-diagnostic or unsatisfactory\u003c\/li\u003e\n  \u003cli\u003eBenign\u003c\/li\u003e\n  \u003cli\u003eAtypia of undetermined significance or follicular lesion of undetermined significance (AUS\/FLUS)\u003c\/li\u003e\n  \u003cli\u003eFollicular neoplasm or suspicious for a follicular neoplasm\u003c\/li\u003e\n  \u003cli\u003eSuspicious for malignancy\u003c\/li\u003e\n  \u003cli\u003eMalignant\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eApproximately \u003cstrong\u003e20% of FNA results\u003c\/strong\u003e fall into the \"AUS\/FLUS\" category, which is a gray zone that can be challenging for doctors and stressful for patients. In these cases, additional imaging and sometimes molecular testing is needed to clarify the diagnosis.\u003c\/p\u003e\n\n\u003ch3\u003eTI-RADS: A Standardized Scoring System\u003c\/h3\u003e\n\n\u003cp\u003eThe \u003cstrong\u003eAmerican College of Radiologists (ACR)\u003c\/strong\u003e has developed a management system called the \u003cstrong\u003eThyroid Imaging Reporting and Data System (TI-RADS)\u003c\/strong\u003e. This system is increasingly used by radiologists and clinicians to plan the management of thyroid tumors, which may include FNA biopsy, surgery, or radiotherapy. TI-RADS criteria are based on five features: \u003cstrong\u003ecomposition, echogenicity, shape, margins, and echogenic foci\u003c\/strong\u003e. Each criterion is scored based on risk levels, ranging from benign (TR1) to highly suspicious (TR5).\u003c\/p\u003e\n\n\u003cp\u003eHere is how the five TI-RADS categories guide management decisions:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTR1 (Score 0) — Benign:\u003c\/strong\u003e No FNA required.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTR2 (Score 2) — Not suspicious:\u003c\/strong\u003e No FNA required.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTR3 (Score 3) — Mildly suspicious:\u003c\/strong\u003e Follow-up if nodule is ≥1.5 cm; FNA if ≥2.5 cm; follow-up at 1, 3, and 5 years.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTR4 (Score 4–6) — Moderately suspicious:\u003c\/strong\u003e Follow-up if ≥1.0 cm; FNA if ≥1.5 cm; follow-up at 1, 3, and 5 years.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTR5 (Score ≥7) — Highly suspicious:\u003c\/strong\u003e Follow-up if ≥0.5 cm; FNA if ≥1.0 cm; annual follow-up for up to 5 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe scoring system works as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComposition:\u003c\/strong\u003e Cystic or almost completely cystic (0 points); spongiform (0 points); mixed cystic and solid (1 point); solid or almost completely solid (2 points).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEchogenicity:\u003c\/strong\u003e Anechoic (0 points); hyperechoic or isoechoic (1 point); hypoechoic (2 points); very hypoechoic (3 points).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShape:\u003c\/strong\u003e Wider-than-tall (0 points); taller-than-wide (3 points).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMargin:\u003c\/strong\u003e Smooth (0 points); ill-defined (0 points); lobulated or irregular (2 points); extra-thyroidal extension (3 points).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEchogenic foci:\u003c\/strong\u003e None or large comet-tail artifacts (0 points); macrocalcifications (1 point); peripheral (rim) calcifications (2 points); punctate echogenic foci (3 points).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eResearch by \u003cstrong\u003eWu et al.\u003c\/strong\u003e compared the efficacy of the BSRTC system to the TI-RADS classification and BRAF mutation testing. The BRAF mutation was previously found to have low sensitivity (meaning it misses many cancers) but \u003cstrong\u003ealmost 100% specificity\u003c\/strong\u003e (meaning when it is present, cancer is almost certainly the cause). The BRAF mutation showed similar clinical value to TI-RADS in nodules classified as BSRTC III\/V. Since BRAF mutations are found in 40–45% of papillary thyroid cancers—and PTC is the most common subtype—TI-RADS-derived diagnosis can provide a non-invasive \"radiogenomic\" approach that potentially predicts underlying common genomic alterations in these thyroid tumors.\u003c\/p\u003e\n\n\u003ch3\u003eUltrasound in Medullary Thyroid Cancer\u003c\/h3\u003e\n\n\u003cp\u003eAlthough FNA cytology can detect about half of medullary thyroid cancers, additional imaging is often necessary for an accurate diagnosis. \u003cstrong\u003eZhu et al.\u003c\/strong\u003e conducted a study to assess whether the standard ACR TI-RADS or a modified TI-RADS was better at diagnosing MTC. They analyzed the systems based on sensitivity, specificity, negative predictive value (the probability that a negative test truly means no disease), accuracy, and the Youden index (a measure of overall diagnostic effectiveness). Zhu et al. concluded that the \u003cstrong\u003emodified TI-RADS was a better framework for diagnosing MTC\u003c\/strong\u003e than the standard ACR TI-RADS.\u003c\/p\u003e\n\n\u003ch3\u003eUltrasound Limitations\u003c\/h3\u003e\n\n\u003cp\u003eOther ultrasound-based classification systems exist from the British Thyroid Association (BTA) and the American Association of Clinical Endocrinologists (AACE). These are used based on regional practice guidelines, which are influenced by geographic location and physician training. In the United States, radiologists mostly adhere to ACR and American Board of Radiology (ABR) guidelines, which has led to rapid adoption of TI-RADS.\u003c\/p\u003e\n\n\u003cp\u003eDespite its many strengths, ultrasound is not always predictive of malignancy. \u003cstrong\u003eRam et al.\u003c\/strong\u003e showed that the sensitivity (ability to correctly identify cancer) and specificity (ability to correctly identify benign nodules) of ultrasound in predicting malignancy were \u003cstrong\u003e80% and 68%, respectively\u003c\/strong\u003e. \u003cstrong\u003eBrito et al.'s meta-analysis\u003c\/strong\u003e further showed that studies quote variable levels of diagnostic accuracy for ultrasound, and the degree of accuracy depends heavily on the experience of the physician interpreting the images.\u003c\/p\u003e\n\n\u003cp\u003eThis is why, in patients with a high index of suspicion for primary or recurrent thyroid cancer, additional imaging modalities—including SPECT, CT, and MRI—should be used to rule out disease.\u003c\/p\u003e\n\n\u003ch2 id=\"spect\"\u003eSPECT Scans: Tracking Iodine in the Body\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e123Iodine SPECT\u003c\/strong\u003e (single-photon emission computed tomography) has been an important diagnostic tool for over six decades. It is used to work up indeterminate or suspicious thyroid nodules and to stage thyroid cancer. The technique leverages a natural biological mechanism: \u003cstrong\u003esodium-iodide symporters (NIS)\u003c\/strong\u003e located on the basolateral plasma membrane of thyrocytes (thyroid cells) create a high affinity for iodine. This physiologic mechanism is exploited in both radioiodine imaging and therapy.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWhole-body scintigraphy (WBS)\u003c\/strong\u003e is commonly performed with 123Iodine to determine whether a suspicious or indeterminate thyroid nodule is \"hot\" (meaning it takes up iodine avidly) or \"cold\" (meaning it has diminished iodine uptake). Radioiodine scans are particularly useful in differentiated subtypes of thyroid cancer because these tumors preserve NIS, allowing radioactive iodine to accumulate preferentially in the tumor compared with normal thyroid tissue. The review cites a 39-year-old male patient with metastatic papillary thyroid carcinoma whose 131-Iodine SPECT scan showed uptake indicating follicular adenoma.\u003c\/p\u003e\n\n\u003cp\u003eHowever, there is an important pitfall to understand. As thyroid neoplasms de-differentiate (become more aggressive and less like normal thyroid tissue), they lose their NIS ability, making them appear \"occult\" (hidden) on radioiodine SPECT scans. This is a critical false-negative finding that doctors must watch for.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e131Iodine (131I)\u003c\/strong\u003e emits both beta and gamma particles, making it the perfect \"theranostics\" agent—a substance that can be used for both therapy and diagnosis. It is commonly administered after thyroidectomy (surgical removal of the thyroid), with or without lymph node dissection, to treat residual thyroid tissue and local or distant metastasis. Because of the gamma activity of 131I, SPECT can also be performed to evaluate the patient's response to 131Iodine radioablation. \u003cstrong\u003ePost-ablation SPECT is usually performed within five to nine days\u003c\/strong\u003e after treatment because this timing improves the signal-to-noise ratio, increasing overall sensitivity for detecting distant metastases.\u003c\/p\u003e\n\n\u003ch2 id=\"ct\"\u003eCT Scans: Finding Incidental Nodules\u003c\/h2\u003e\n\n\u003cp\u003eWith the continual increase in the use of CT (computed tomography), unsuspected thyroid nodules are frequently detected on scans ordered for other reasons. The incidental thyroid nodule detection rate on CT of the chest ranges from \u003cstrong\u003e2–65%\u003c\/strong\u003e. Although the majority of these incidental nodules are benign, \u003cstrong\u003e5% are malignant\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eBecause of this, combined with the decade-long trend of increased thyroid cancer incidence, the ACR has published recommendations for managing incidental thyroid nodules found on CT. The review's Figure 4 outlines this clinical work-up:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFor \u003cstrong\u003enon-suspicious nodules\u003c\/strong\u003e in patients whose health is compromised by other medical conditions or limited life expectancy, no additional imaging assessment is warranted (nodules less than 1.5 cm, or 1.5 cm or larger depending on patient health).\u003c\/li\u003e\n  \u003cli\u003eFor \u003cstrong\u003esuspicious nodules\u003c\/strong\u003e, if the patient's health is similar to the general population and the patient is \u003cstrong\u003e35 years or older\u003c\/strong\u003e, nodules measuring \u003cstrong\u003e1 cm or larger\u003c\/strong\u003e should be investigated with ultrasound. For patients \u003cstrong\u003eunder 35 years\u003c\/strong\u003e of age, nodules measuring \u003cstrong\u003e1.5 cm or larger\u003c\/strong\u003e should be investigated. Smaller nodules in each category do not require immediate ultrasound.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThyroid nodules with suspicious features on CT are followed up with ultrasound and may require ultrasound-guided FNA biopsy to determine whether the lesion is benign or malignant. Although CT is not the initial modality of choice for evaluating primary thyroid cancer, it is extremely useful for \u003cstrong\u003estaging\u003c\/strong\u003e—specifically, detecting metastasis (spread of disease). In cases where the primary thyroid lesion extends below the sternum (substernal extension) or there is concern for airway compromise, CT is the preferred diagnostic modality. The review illustrates this with the case of a 39-year-old male with metastatic papillary thyroid carcinoma whose CT showed a heterogeneously enhancing nodule eroding through the thyroid capsule.\u003c\/p\u003e\n\n\u003ch2 id=\"petct\"\u003ePET\/CT Scans: Detecting Aggressive Tumors\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePET\/CT\u003c\/strong\u003e (positron emission tomography\/computed tomography) is widely used for staging and restaging of malignancies because it simultaneously acquires structural (anatomical) and functional (metabolic) information. The logic for using PET\/CT in thyroid cancer follows directly from the biology we discussed earlier:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eDifferentiated thyroid neoplasms preserve NIS and are adequately assessed on SPECT scans.\u003c\/li\u003e\n  \u003cli\u003eDe-differentiated or poorly differentiated thyroid neoplasms are \"occult\" on radioiodine SPECT because they lose NIS.\u003c\/li\u003e\n  \u003cli\u003eHowever, these aggressive neoplasms have increased metabolic activity, which makes them visible on \u003cstrong\u003e18Fluorodeoxyglucose (FDG) PET\/CT\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn patients with \u003cstrong\u003ehigh levels of thyroglobulin\u003c\/strong\u003e (a protein produced by thyroid cells, used as a tumor marker) and a \u003cstrong\u003enegative iodine scan\u003c\/strong\u003e, PET\/CT can assess the extent of metastatic disease, assist in radiotherapy planning, and evaluate the patient's response to treatment. The quantitative measurements from FDG-PET\/CT have been shown to have predictive and prognostic value. As such, FDG PET\/CT is the \u003cstrong\u003epreferred modality for restaging patients with de-differentiated thyroid neoplasms\u003c\/strong\u003e for whole-body assessment.\u003c\/p\u003e\n\n\u003cp\u003eThe review provides two illustrative cases:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA 66-year-old female with poorly differentiated thyroid carcinoma whose FDG PET\/CT showed increased FDG uptake in the thyroid nodule, along with FDG-avid metastasis to an ipsilateral cervical chain lymph node.\u003c\/li\u003e\n  \u003cli\u003eA 74-year-old female with anaplastic thyroid carcinoma whose PET\/CT showed increased FDG uptake within an enlarged thyroid with irregular margins encasing the trachea (windpipe).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, PET\/CT has important \u003cstrong\u003elimitations\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFalse positives:\u003c\/strong\u003e FDG PET\/CT has increased rates of false positives when there is co-existing infection and\/or inflammation. It is often difficult to distinguish radiation-related inflammation from residual tumor, especially after treatment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEquivocal cases\u003c\/strong\u003e may require further evaluation with other modalities (MRI, PET\/MRI) and\/or biopsy to improve diagnostic specificity.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited resolution for small lung metastases:\u003c\/strong\u003e Whole-body PET\/CT has larger slice thickness, which limits assessment of pulmonary micrometastasis (very small lung deposits). In such cases, dedicated high-resolution CT of the chest is the best diagnostic modality.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited soft tissue resolution:\u003c\/strong\u003e If there is concern for central nervous system (CNS) or spinal metastasis, MRI or PET\/MRI are the preferred diagnostic modalities.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"mri\"\u003eMRI: Detailed Soft Tissue Imaging\u003c\/h2\u003e\n\n\u003cp\u003eBecause of its cost and limited availability compared to other modalities, \u003cstrong\u003eMRI (magnetic resonance imaging)\u003c\/strong\u003e is most frequently used as a second-line tool for characterizing suspicious regions. Ultrasound remains the modality of choice for initial diagnosis and follow-up, but when recurrence or relapse is suspected, MRI is utilized because of its \u003cstrong\u003esuperior soft tissue resolution\u003c\/strong\u003e relative to ultrasound, CT, PET\/CT, and SPECT.\u003c\/p\u003e\n\n\u003cp\u003eMRI is the modality of choice for surveying recurrence in high-risk patients, including those with a family history of thyroid cancer (familial neoplasms) or aggressive initial cancers with positive surgical margins. Improved contrast and soft tissue resolution on newer MRI techniques provide more precise evaluation of tumor extent and infiltration of surrounding tissues such as blood vessels, nerves, and bones.\u003c\/p\u003e\n\n\u003cp\u003eSeveral advanced MRI techniques are improving diagnostic accuracy:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiffusion weighted imaging (DWI)\u003c\/strong\u003e, coupled with changes in other sequences (T1- and T2-weighted), can help discriminate between benign and malignant thyroid lesions.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePerfusion MRI\u003c\/strong\u003e, which evaluates the degree of tumor vascularity (blood vessel supply) and tumoral blood flow relative to normal tissue, has also been shown to help distinguish benign from malignant lesions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe review includes the case of a 37-year-old female diagnosed with papillary thyroid carcinoma whose MRI showed a heterogeneously enhancing nodule in the anterior aspect of the left thyroid lobe, with well-circumscribed borders and no evidence of lymph node involvement or tracheal invasion.\u003c\/p\u003e\n\n\u003cp\u003eHistorically, implantable cardiac devices and other metallic implants were a limitation of MRI. However, because of the clinical need for accurate diagnosis, manufacturers have developed \u003cstrong\u003eMRI-compatible devices\u003c\/strong\u003e, and newer MRI protocols have been developed by the American College of Radiology to overcome these limitations.\u003c\/p\u003e\n\n\u003ch2 id=\"petmri\"\u003ePET\/MRI: Combining Two Powerful Technologies\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePET\/MRI\u003c\/strong\u003e is a hybrid modality that provides simultaneous acquisition of PET and MRI data. It combines the individual strengths of both technologies, allowing it to overcome many of the limitations of PET\/CT.\u003c\/p\u003e\n\n\u003cp\u003eResearch by \u003cstrong\u003eBinse et al.\u003c\/strong\u003e demonstrated several advantages of PET\/MRI in thyroid cancer:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePET is more accurate in diagnosing the spatial extent of disease.\u003c\/li\u003e\n  \u003cli\u003eIt provides better morphologic (structural) characterization, especially in the operative bed (the area where surgery was performed).\u003c\/li\u003e\n  \u003cli\u003eIt shows improved detection of disease in the brain, bones, and spinal canal.\u003c\/li\u003e\n  \u003cli\u003eThe PET detectors in PET\/MRI are more sensitive and can detect more lesions than conventional PET\/CT detectors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIn the postoperative and post-ablative setting, MRI is better than CT at assessing residual and\/or recurrent disease in the treatment region. Because the MRI component of PET\/MRI does not require ionizing radiation, there is \u003cstrong\u003eoverall decreased radiation exposure\u003c\/strong\u003e from PET\/MRI compared to PET\/CT.\u003c\/p\u003e\n\n\u003cp\u003eIn a study by \u003cstrong\u003eJentzen et al.\u003c\/strong\u003e, the quantitative performance of \u003cstrong\u003e124I PET\/MRI and 124I PET\/CT\u003c\/strong\u003e was compared directly. The study showed comparable quantitative PET performance between the two modalities, further suggesting that PET\/MRI can be reliably used for evaluation of thyroid cancer in both initial staging and follow-up settings.\u003c\/p\u003e\n\n\u003ch2 id=\"theranostics\"\u003eTheranostics: Combining Diagnosis and Treatment\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eTheranostics\u003c\/strong\u003e is a term that combines \"therapy\" and \"diagnostics.\" It incorporates diagnostic methods and therapeutics to develop precision medicine techniques that give patients personalized treatments. \u003cstrong\u003eRadiotheranostics\u003c\/strong\u003e is the subset that uses radioactive components, which can serve both diagnostic imaging and therapeutic purposes.\u003c\/p\u003e\n\n\u003cp\u003eOne of the first radiotheranostic agents ever used was \u003cstrong\u003eradioiodine (131I)\u003c\/strong\u003e for the treatment of thyroid cancer. The presence of NIS in differentiated thyroid neoplasms allows tumors to be both imaged and ablated (destroyed) with the same agent. This dual capability is the essence of theranostics.\u003c\/p\u003e\n\n\u003cp\u003eThe authors explain this concept using a compelling clinical example: a 39-year-old male patient diagnosed with metastatic papillary thyroid carcinoma presented with 131-Iodine uptake on SPECT scan, indicating follicular adenoma. The same molecular mechanism that allows iodine to be taken up by thyroid cells for imaging also allows radioactive iodine to be delivered as therapy directly to the cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eThis approach is a natural fit for thyroid cancer care because the thyroid gland's unique iodine-avid biology provides a built-in targeting mechanism. As more molecular targets are identified, theranostic approaches are likely to expand beyond radioiodine to include other radioactive agents coupled to tumor-specific molecules.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eClinical Implications for Patients\u003c\/h2\u003e\n\n\u003cp\u003eSo what does all of this mean for patients? Several key takeaways emerge from this review:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFirst, incidental findings are increasingly common.\u003c\/strong\u003e If you have a CT scan of the chest for an unrelated reason (such as a cough, chest pain, or trauma) and the radiologist spots a thyroid nodule, this does not mean you have cancer. The vast majority of these incidental nodules are benign. However, the \u003cstrong\u003e5% malignancy rate\u003c\/strong\u003e means that follow-up ultrasound is warranted for suspicious nodules according to the ACR guidelines—especially in younger patients (under 35) and when nodules are 1 cm or larger.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSecond, the diagnostic work-up is now highly standardized.\u003c\/strong\u003e The TI-RADS system gives doctors a clear, evidence-based framework for deciding which nodules need biopsy and which can be safely monitored. The Bethesda system standardizes how biopsy results are reported, reducing ambiguity and helping patients understand their results.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThird, imaging is not a one-size-fits-all approach.\u003c\/strong\u003e Different imaging modalities serve different purposes:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUltrasound\u003c\/strong\u003e is the first step—it's safe, cheap, and excellent for characterizing nodules in the neck.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSPECT\u003c\/strong\u003e tells doctors whether the tumor takes up iodine, which predicts whether radioiodine therapy will work.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCT\u003c\/strong\u003e is best for staging and for evaluating airway involvement or substernal extension.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePET\/CT\u003c\/strong\u003e is the go-to for aggressive, de-differentiated tumors that don't show up on iodine scans, and for patients with rising thyroglobulin levels but negative iodine imaging.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMRI\u003c\/strong\u003e provides the best soft tissue detail for evaluating recurrence, especially in high-risk patients, and for assessing spread to the brain or spine.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePET\/MRI\u003c\/strong\u003e combines the strengths of PET and MRI with less radiation exposure, and is emerging as a powerful tool for both staging and follow-up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFourth, genetics are changing the game.\u003c\/strong\u003e Knowing whether a tumor has a BRAF, RAS, RET, or TP53 mutation can help predict behavior and guide treatment decisions. Molecular testing panels like ThyroSeqv2™ are helping doctors diagnose indeterminate nodules and choose targeted therapies where appropriate.\u003c\/p\u003e\n\n\u003cp\u003eFor the 98% of patients with well-differentiated thyroid cancer, the prognosis remains excellent. But for the small but real group with aggressive subtypes—particularly anaplastic thyroid cancer, where median survival is only 3–7 months—accurate, rapid diagnosis and the right imaging tools can make a meaningful difference in treatment planning and outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Review\u003c\/h2\u003e\n\n\u003cp\u003eAs with any review article, there are important limitations to keep in mind. First, ultrasound accuracy varies significantly depending on the experience of the interpreting physician, as documented in Brito et al.'s meta-analysis. A test that is 80% sensitive and 68% specific (per Ram et al.) means that ultrasound will miss some cancers and will also flag some benign nodules as suspicious.\u003c\/p\u003e\n\n\u003cp\u003eSecond, PET\/CT has a notable false-positive rate in the setting of infection or inflammation. This means that a positive PET scan after radiation therapy could reflect treatment-related inflammation rather than residual cancer—a scenario that creates diagnostic uncertainty and sometimes leads to unnecessary biopsies.\u003c\/p\u003e\n\n\u003cp\u003eThird, the standard TI-RADS system may be suboptimal for certain tumor types, such as medullary thyroid cancer, where a modified TI-RADS framework appears to perform better (per Zhu et al.). This suggests that the one-size-fits-all approach to imaging interpretation may need refinement for less common subtypes.\u003c\/p\u003e\n\n\u003cp\u003eFourth, this is a review article, not a prospective clinical trial. It synthesizes existing evidence rather than presenting new patient data. Some of the cited studies are small or were conducted at single institutions. The field is evolving rapidly, and some of the technologies discussed (particularly PET\/MRI) may not be widely available in all clinical settings.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the cost and availability of advanced imaging (MRI, PET\/CT, PET\/MRI) remain barriers. MRI is used second-line \"due to cost and limited availability,\" and PET\/MRI is not yet a standard tool in most community practices.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here are practical steps patients can take:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your risk factors.\u003c\/strong\u003e If you have a history of radiation exposure (especially to the head or neck), a family history of thyroid cancer (particularly medullary thyroid cancer), or are over 60, talk to your doctor about appropriate screening.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't panic over incidental nodules.\u003c\/strong\u003e If a CT scan performed for another reason finds a thyroid nodule, follow your doctor's guidance. Most incidental nodules are benign. The ACR has clear criteria for which nodules need further evaluation based on size, suspicious features, and your age.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your TI-RADS score.\u003c\/strong\u003e If you have an ultrasound, ask your radiologist or doctor what your TI-RADS category was (TR1 through TR5). Higher scores mean higher suspicion and more aggressive follow-up is warranted.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about molecular testing.\u003c\/strong\u003e If your FNA biopsy comes back as \"indeterminate\" (such as atypia of undetermined significance), ask whether next-generation sequencing panels like ThyroSeqv2™ could help clarify whether your nodule is benign or malignant.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExpect a multi-modality approach for aggressive disease.\u003c\/strong\u003e If you have poorly differentiated or anaplastic thyroid cancer, or if you have rising thyroglobulin with a negative iodine scan, ask whether FDG PET\/CT is appropriate for restaging. For brain or spine concerns, MRI or PET\/MRI is preferred.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow the signs of recurrence.\u003c\/strong\u003e Because thyroid cancer recurs in approximately 20% of patients, ongoing surveillance is critical. Based on this review, high-risk patients (those with familial neoplasms or aggressive initial cancers with positive margins) should be monitored with MRI as the modality of choice.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eParticipate in shared decision-making.\u003c\/strong\u003e The choice of imaging modality depends on many factors, including tumor type, stage, treatment history, and your overall health. Ask your care team why they are recommending a particular scan and what they hope to learn from it.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe era of precision imaging has transformed thyroid cancer care. With the right combination of ultrasound, nuclear medicine scans, CT, MRI, and molecular testing, patients can receive more accurate diagnoses, more targeted treatments, and better overall outcomes.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the survival rate for thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eThe median 5-year survival rate for thyroid cancer was 98% between 2009 and 2015. However, this varies by subtype. Anaplastic thyroid cancer is much more aggressive, with a median survival of only 3 to 7 months and a 1-year survival rate of 10–20%. Women are more commonly affected, accounting for 75% of diagnoses.\u003c\/p\u003e\n\u003ch3\u003eHow common is thyroid cancer and who is most likely to get it?\u003c\/h3\u003e\n\u003cp\u003eThyroid cancer affects 1.3% of the population and accounts for 2.1% of all cancer diagnoses worldwide. The average age at diagnosis is 48 years. Women are three times more likely to be diagnosed than men. Elderly patients have a higher incidence and worse prognosis. About 20% of patients experience recurrence after initial treatment.\u003c\/p\u003e\n\u003ch3\u003eIf a CT scan for another reason finds a thyroid nodule, what happens next?\u003c\/h3\u003e\n\u003cp\u003eMost incidental thyroid nodules are benign, but 5% are malignant. According to the American College of Radiology, suspicious nodules measuring 1 cm or larger in patients 35 or older should be investigated with ultrasound. For patients under 35, nodules 1.5 cm or larger need ultrasound. Some small non-suspicious nodules may not require any additional imaging, especially in patients with limited life expectancy.\u003c\/p\u003e\n\u003ch3\u003eWhat is TI-RADS and what does my score mean?\u003c\/h3\u003e\n\u003cp\u003eTI-RADS is a standardized scoring system used by radiologists to classify thyroid nodules from TR1 (benign) to TR5 (highly suspicious). It evaluates composition, echogenicity, shape, margins, and echogenic foci. Higher scores mean higher suspicion of cancer and usually lead to more frequent follow-up or biopsy. For example, TR5 nodules 1 cm or larger typically require fine needle aspiration biopsy.\u003c\/p\u003e\n\u003ch3\u003eWhat is a 'hot' or 'cold' nodule on an iodine SPECT scan?\u003c\/h3\u003e\n\u003cp\u003eA SPECT scan with radioactive iodine shows how much iodine the thyroid nodule takes up. A 'hot' nodule takes up iodine avidly and is more likely benign. A 'cold' nodule has diminished uptake. Well-differentiated thyroid cancers often preserve iodine uptake, making SPECT useful. However, aggressive, de-differentiated tumors lose this ability and may appear 'occult' or hidden on iodine scans.\u003c\/p\u003e\n\u003ch3\u003eWhen is a PET\/CT scan more useful for thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003ePET\/CT is especially helpful for aggressive, de-differentiated thyroid cancers that do not show up on iodine scans. These tumors have increased metabolic activity and appear on FDG PET\/CT. It is also used when thyroglobulin levels are high but an iodine scan is negative. However, PET\/CT can have false positives from infection or inflammation and has limited resolution for very small lung metastases.\u003c\/p\u003e\n\u003ch3\u003eWhat are theranostics in thyroid cancer treatment?\u003c\/h3\u003e\n\u003cp\u003eTheranostics combines therapy and diagnostics. Radioiodine (131I) is a classic radiotheranostic agent. Because well-differentiated thyroid cancer cells take up iodine, the same substance can be used to image and also treat the cancer. This approach delivers radioactive iodine directly to cancer cells, allowing both diagnosis and therapy in one step. This is a key part of precision medicine for thyroid cancer.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal Article Title:\u003c\/strong\u003e Thyroid cancer diagnosis in the era of precision imaging\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e \u003ca href=\"https:\/\/doi.org\/10.21037\/jtd.2019.08.37\" target=\"_blank\" rel=\"noopener\"\u003e10.21037\/jtd.2019.08.37\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Kimberley-Jane Bonjoc, Hannah Young, Susanne Warner, Thomas Gernon, Ellie Maghami, Ammar Chaudhry\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eInstitutions:\u003c\/strong\u003e Departments of Imaging Administration, Surgery, and Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA, USA\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Journal of Thoracic Disease, Vol 12, No 9, September 2020, pages 5128–5139\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication Dates:\u003c\/strong\u003e Submitted Jul 29, 2019; Accepted Aug 21, 2019\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.21037\/jtd.2019.08.37\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research published in a medical journal. It has been adapted to make the information accessible to patients and caregivers while preserving all key data, statistics, and clinical implications from the original review article. For any medical decisions, always consult your healthcare provider.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400024965276,"sku":null,"price":0.0,"currency_code":"CHF","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ch\/products\/understanding-thyroid-cancer-diagnosis-in-the-era-of-precision-imaging-a-patients-guide","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}